Composed of experienced leaders from across the health care system, the Scientific Advisory Panel helps set IVI research priorities, steers the research agenda in collaboration with scientific leadership, and provides guidance on ongoing research efforts. Panel members represent diverse perspectives from across the health care community, including academia, patient advocates, payers, providers, and the life sciences industry. Their role is to provide advice and ensure the credibility and rigor in the research and policy products, and to ensure all parties have a voice in IVI activities.
Darius Lakdawalla, PhD
Acting Chair, Scientific Advisory Panel
Darius Lakdawalla, PhD
Dr. Lakdawalla holds the Quintiles Chair in Pharmaceutical and Regulatory Innovation at the University of Southern California, where he sits on the faculties of the School of Pharmacy and the Sol Price School of Public Policy. He is also the Director of Research at USC’s Leonard D. Schaeffer Center for Health Policy and Economics, one of the nation’s premiere health policy research centers. Dr. Lakdawalla is also a Research Associate at the National Bureau of Economic Research, and an Associate Editor at the Review of Economics and Statistics, the American Journal of Health Economics, and the Journal of Health Economics. He is a consultant to Precision Health Economics, and an investor in its parent company, Precision Medicine Group. Dr. Lakdawalla holds a PhD in economics from the University of Chicago, and a BA in Mathematics and Philosophy from Amherst College.
Patient Advocate Foundation
Alan Balch, PhD
Dr. Balch has nearly fifteen years of executive leadership in the non-profit sector with an emphasis on consensus building and collaboration. He has led numerous federal advocacy efforts on a range of issues both that the legislative and regulatory level. He became the CEO of both the Patient Advocate Foundation (PAF) and National Patient Advocate Foundation (NPAF) in 2013. From 2006-2013, he served as the Vice President of the Preventive Health Partnership – a national health promotion collaboration between the American Cancer Society, American Diabetes Association, and American Heart Association. Prior to 2006, Dr. Balch was the Executive Director of Friends of Cancer Research.
Dr. Balch has served on the Executive Board of PAF and NPAF since 2007. He also serves on numerous advisory boards and committees.
He earned his PhD in environmental studies with a concentration in political economy from the University of California, Santa Cruz; master’s degree in environmental sciences in 1997 from the University of Texas in San Antonio; and bachelor’s degree (cum laude) in biology in 1994 from Trinity University in San Antonio.
Geisinger Health Plan
John Bulger, DO, MBA
John Bulger, DO, MBA, is the Chief Medical Officer for Geisinger Health Plan, Geisinger Indemnity Insurance Company, and Geisinger Quality Options, Incorporated. Dr. Bulger also serves as the Chief Medical Officer for Population Health at Geisinger Health System. In this key role, he works with Geisinger Health System and community providers to improve the quality of medical care for patients and members. Prior to joining Geisinger Health Plan, Dr. Bulger was the Chief Quality Officer at Geisinger Health System. He currently serves on various regional and national groups with the continued focus of striving to improve the quality of medical care. Dr. Bulger also chairs the Society of Hospital Medicine’s committee on healthcare quality and patient safety.
Randy Burkholder is the Vice President of Policy and Research at the Pharmaceutical Research and Manufacturers of America (PhRMA). Mr. Burkholder leads PhRMA work on policy solutions for supporting continued biopharmaceutical innovation and high-quality, patient-centered health care, including pavement and delivery reform, quality measurement, appropriate use and patient adherence, evidence-based medicine and health technology assessment, value of innovation and personalized medicine. Mr. Burkholder represents PhRMA at federal agencies and advisory bodies including the Medicare Evidence Development and Coverage Advisory Committee, CMS’ Technical Expert Panel on oncology, and the Federal Coordinating Council for Comparative Effectiveness Research. He is also a former member of the Board of Directors of the Personalized Medicine Coalition and serves on the Steering Committee of the Partnership to Improve Patient Care and the advisory committee for the Turning the Tide Against Cancer Initiative.
Mr. Burkholder has over 20 years of experience in health care policy, advocacy and communications in the medical technology and pharmaceutical industries. Prior to joining PhRMA, Mr. Burkholder was Associate Vice President for Public Affairs at AdvaMed, the leading association of the medical device and diagnostic industries.
American Express (Former)
Wayne N. Burton, MD
Wayne N. Burton, MD is Adjunct Professor of Occupational Medicine, University of Illinois at Chicago and Clinical Associate Professor of Medicine, Feinberg School of Medicine, Northwestern University. He was formerly the Chief Medical Officer for American Express and for JPMorgan Chase. He is Board Certified in Internal Medicine and a Fellow of the American College of Physicians and the American College of Occupational and Environmental Medicine. He has been the recipient of several awards including the Jonas Salk Leadership Award from the March of Dimes, the Health Leadership Award from the American College of Occupational and Environmental Medicine among others. He serves on several national advisory boards and on the editorial board of Population Health Management. Dr. Burton has published over 100 papers in peer reviewed medical journals.
National Pharmaceutical Council
Robert W. Dubois, MD, PhD
Robert W. Dubois, MD, PhD, is the Chief Science Officer and Executive Vice President of the National Pharmaceutical Council (NPC). In this role at NPC, he oversees the company’s research on policy issues as they relate to the role of real-world evidence in decision making, how to determine the value of health care services, the relationship between access and health outcomes, and the approaches to maintain an environment that supports health innovation. Dr. Dubois brings over 25 years of experience in health care research, with a key focus on understanding and ensuring that patients receive high value health care. Dr. Dubois is also a member of the Medicare Evidence Development and Coverage Advisory Committee, Advisory Board of the Institute for Clinical and Economic Review, the Associate Editor of the Journal of Comparative Effectiveness Research and on the editorial board for Health Affairs and The American Journal of Managed Care. He has published more than 150 peer-reviewed articles.
Biotechnology Innovation Organization
Daniel Durham, MPP
Daniel Durham is the Executive Vice President for Health Policy at the Biotechnology Innovation Organization (BIO) where he leads the development of policy positions promoting biomedical innovation and ensuring patient access to biopharmaceuticals. Previously, he held policy leadership positions at America’s Health Insurance Plans and the Pharmaceutical Research and Manufacturers of America. Mr. Durham also served as acting Deputy Assistant Secretary for Health Policy in ASPE at the U.S. Department of Health and Human Services and held key policy positions at the Social Security Administration, the Office of Management and Budget, AARP, and the California Legislative Analyst’s Office. He holds a Master’s degree in Public Policy from Duke University and a Bachelor’s degree in Government and Philosophy from the University of Notre Dame.
Patricia Fritz, MS
Patty Fritz is vice president, U.S. Corporate Affairs for UCB, Inc, overseeing policy, government affairs, advocacy, patient engagement, communications and UCBCares®. Patty leads efforts to create value for patients and their families through strategic engagement and positively influencing the healthcare environment and policy landscape. She is a champion of innovative projects to spotlight the importance of access and care for people living with severe diseases.
Having been with UCB for more than 20 years, Patty has made a significant impact in different leadership roles including Regulatory Affairs, Operational Excellence, Government Affairs and Policy. Patty led the regulatory efforts for UCB’s first product filing – Keppra® (levetiracetam) – and oversaw the FDA approval process for many of UCB’s other products.
Outside of UCB, Patty serves on the board of directors of Georgia BIO and The Carter Center Board of Councilors.
Patty holds a master’s degree in health care policy and administration from Mercer University, a Bachelor of Science degree in management and technology from the University of Maryland and is also a graduate of Summers County School of Nursing.
Jan Hansen, PhD
Jan Hansen, PhD, is Vice President of the Evidence for Access Unit within Genentech’s US Medical Affairs. Her unit is staffed with researchers who are uniquely positioned and skilled to address both the value and quality drivers of access in the US. These researchers are tasked to consider both value and quality evidence when they develop access strategies and tactics. Jan is a seasoned executive with more than twenty-five years of experience in the health care and pharmaceutical industries. Jan’s pharmacoeconomics and health outcomes expertise were acquired throughout her vast career experiences in patient-based research, health care consulting, sales strategy and execution, and in both global and US focused outcomes research. She has held positions with increasing leadership responsibility at several well-regarded companies, including PCS-Pharmaceutical Data Services (now CVS-Caremark), NDC Health, Wolters Kluwer Health, Glaxo Wellcome (now GlaxoSmithkline), and Allergan. Her professional accomplishments have been recognized by several professional organizations and resulted in numerous appointments, including: the University of Iowa College of Pharmacy Advisory Council, past Chair and current member of the University of Washington College of Pharmacy’s Corporate Advisory Council, Board member (representing Genentech) of the National Pharmaceutical Council (NPC), member of the Drug Information Association (DIA) Advisory Council of North America, past NPC Corresponding Officer and Research Committee member (representing Allergan), current member of the Academy Health Institution Council, and Foundation of Managed Care Pharmacy (FMCP) Board of Trustee. Jan is a licensed pharmacist and holds a Ph.D. in Pharmacy Administration from the University of South Carolina at Columbia. She is also a speaker and guest lecturer on topics related to pharmacoeconomics and outcomes research. Jan’s ultimate passion is “building”; she takes great pride in building organizations and fostering young, innovative-thinking, yet applied researchers. For Jan, there is no greater joy than watching these researchers flourish and making a difference to patients’ lives.
Partners Healthcare System
Gregg S. Meyer, MD, MSc
Gregg S. Meyer, MD, MSc, is the Chief Clinical Officer of the Partners Healthcare System in Boston, Massachusetts, responsible for overall direction, operations, and management of system aspects of healthcare delivery throughout the Partners Healthcare delivery system. Dr Meyer previously served as the Chief Clinical Officer and Executive Vice-President for Population Health at Dartmouth-Hitchcock Medical Center, and held leadership positions at the Massachusetts General Hospital and Massachusetts General Physicians Organization (MGPO), the Agency for Healthcare Research and Quality (AHRQ), and Uniformed Services University of the Health Sciences (USUHS) where he served as a Colonel in the United States Air Force. He is a Phi Beta Kappa and summa cum laude graduate of Union College and magna cum laude graduate of Albany Medical College. He earned a Masters degree at Oxford University where he was a Rhodes Scholar. In addition, he holds a masters degree from the Department of Health Policy and Management from the Harvard School of Public Health and served as a fellow in the U.S. Senate Labor and Human Resources Committee’s health office.
Harvard Pilgrim Health Care
Michael Sherman, MD
Dr. Michael Sherman serves as chief medical officer and senior vice president for Harvard Pilgrim Health Care. Dr. Sherman is responsible for Harvard Pilgrim’s medical trend management, provider engagement strategy, medical informatics, wellness and health promotion initiatives, care and disease management services, pharmacy services, NCQA accreditation and quality and utilization management programs and has been a leader in driving adoption of outcomes-based provider and pharmaceutical contracts. He also serves on the faculty of Harvard Medical School’s Department of Population Medicine, as chair of the Board of Managers of the Harvard Pilgrim Health Care Institute and on the Advisory Board of the Institute for Clinical and Economic Review (ICER). Dr. Sherman also is the current chair for AHIP’s CMO Leadership Council, comprised of chief medical officers from health plans throughout the United States.
Vipan C. Sood, PharmD
Vipan joined AbbVie in 2014 and is currently serving as Vice President, HEOR, Virology/EndoMetabolics/Neuroscience. Prior to joining AbbVie, he was Senior Director, Medical Affairs & HEOR for Mitsubishi Tanabe Pharma America, Inc. He also held positions at GSK & Sanofi, including Executive Director, HEOR at GSK and Senior Director, HEOR at Sanofi. Vipan has a degree in Pharmacy and also attended University of Illinois for his MBA.
MedStar Health Research Institute
Neil Weissman, MD
As Chief Scientific Officer, Dr. Weissman provides leadership for the development and implementation of specific scientific priorities, with a commitment to further advancing MedStar health as an academic healthcare system. As president of the Research Institute, he is responsible for the overall strategic and operational direction of the research arm of MedStar Health.
Dr. Weissman’s research interests include the use of cardiovascular ultrasound imaging in clinical trials on valvular heart disease, prosthetic heart valves, and intravascular therapeutics. He has served as principal investigator for numerous national and international multi-center trials, served on several national organizations and editorial boards, and written hundreds of original reports published in high profile peer-reviewed journals. He is frequently invited to serve as an expert on the U.S. Food and Drug Administration advisory panels and National Institutes of Health commissions and held many national leadership positions, including past president of the American Society of Echocardiography and past chair of the American College of Cardiology’s Imaging Council.
Dr. Weissman received his medical degree from Cornell University Medical College in New York. He completed his internship, residency, and chief residency in Internal Medicine at New York Hospital. He followed his residency training with a clinical and research fellowship in Cardiology and a fellowship in Cardiac Ultrasound at Massachusetts General Hospital in Boston.
Donald D. Yin, PhD
Dr. Yin is Vice President and Head of Economic and Data Sciences at the Center for Observational and Real-world Evidence (CORE) at Merck. His previous positions at Merck included head of CORE Hospital and Specialty Care Product Line, head of Global Health Outcomes, head of Market Access and Public Policy at Merck in China, and Executive Director and head of Global Market Access Strategy. He has more than 20 years of academic and industry experience in health economics and outcomes research, health technology assessment, comparative effectiveness research, and health services research. He has authored or co-authored more than 80 peer-reviewed scientific articles and published more than 150 abstracts at national and international scientific meetings.
Before joining the pharmaceutical industry in 1996, Dr. Yin was an Assistant Professor of Health Economics at the University of Pennsylvania and Senior Fellow at the Leonard Davis Institute of Health Economics. He received his Ph.D. from the Wharton School of the University of Pennsylvania and a Master of Science degree from the California Institute of Technology. He received his B.S. degree in Applied Mathematics and an M.S. degree in Econometrics from the Huazhong University of Science and Technology in Wuhan, China.
Martin Zagari, MD
Prior to Amgen, between 1997 and 2005, Dr. Zagari held various positions at Johnson & Johnson in Health Economics, Medical Affairs, and Strategic Marketing. These positions included: Executive Director in J&J Corporate Strategic Marketing for the erythropoietic agents, Medical Director for erythropoietic treatments in oncology at Ortho Biotech, and Director positions in Health Economics.
Between 1994 and 1997, Dr. Zagari worked in Health Economics and Outcomes consulting at Technology Assessment Group/Lewin-TAG, based in San Francisco.
Martin received his MD from Stanford University, an MBA from Rutgers University, and BS in Biology from the University of North Carolina at Chapel Hill and is trained in anesthesiology.